Highly effective new anticancer drug shows few side effects in animal studies
A new drug known as OTS964 can eliminate eradicate aggressive human lung cancers that were transplanted into mice, according to recent research.
Anti-Cancer
Potential therapy for rare, drug-resistant GISTs
By screening a library of US FDA-approved anticancer drugs that previously wouldn’t have been considered as a treatment for a rare type of cancer, scientists were surprised to find several potential possibilities.
Suppressed protein halted melanoma metastasis
Inhibiting one protein eliminated metastasis of melanoma in lab studies, a finding that could lead to targeted therapies for a range of cancers.
Study shows cause of and potential cure for aggressive leukemia
Excessive levels of interleukin-15 initiate large granular lymphocyte (LGL) leukemia, but also represent a promising therapeutic target.
Everolimus shrinks astrocytoma brain tumors
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
All PARP inhibitors not created equal in terms of PARP-trapping power
Research findings indicate that PARP inhibitors vary from one another in their ability to trap PARP proteins.
Repeat glioblastoma surgeries may prolong life
Persons with glioblastoma who undergo repeated resections can have improved survival, indicate the findings of a recent study.
Noninvasive technique predicts patients’ response to chemotherapy
Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Noninvasive technique predicts patients’ response to chemotherapy
Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Triple-drug regimen controls brain metastasis in breast cancer
Combining trastuzumab and lapatinib with an anti-VEGFR2 antibody dramatically improved survival in HER2 breast cancer with brain metastases.
-
Loading...
-
Loading...
